Nicardipine


Generic Medicine Info
Administration
Regular-release: May be taken with or without food. Avoid grapefruit juice 1 hr before or 2 hr after a dose.
Extended-release: Should be taken with food. Avoid grapefruit juice 1 hr before or 2 hr after a dose. Avoid taking w/ high fat meals. Swallow whole, do not crush/chew.
Contraindications
Patients w/ advanced aortic stenosis, unstable angina, cardiogenic shock. acute angina attack. Use w/in 1 mth of MI.
Special Precautions
Patients w/ acute cerebral infarction or haemorrhage, CHF, HTN associated w/ phaeochromocytoma, portal HTN. Hepatic and renal impairment. Pregnancy and lactation. Monitoring Parameters BP and heart rate should be monitored carefully esp during initiation of therapy and titration or upward adjustment of dosage.
Adverse Reactions
Pedal oedema, tachycardia, hypotension, abnormal ECG, palpitations, flushing, headache, asthenia, dizziness, paraesthesia, somnolence, myalgia, nausea, vomiting, constipation, dyspepsia, dry mouth, rash, polyuria, dyspnoea, hypokalaemia, increased urinary frequency, haematuria, nocturia.
Drug Interactions
Concomitant use w/ β-blockers may precipitate or worsen heart failure. May alter serum levels w/ CYP3A4 inducers (e.g. carbamazepine, rifampicin) or inhibitors (e.g. cimetidine). May increase serum levels of ciclosporin, tacrolimus, sirolimus and digoxin.
ATC Classification
C08CA04 - nicardipine ; Belongs to the class of dihydropyridine derivative selective calcium-channel blockers with mainly vascular effects. Used in the treatment of cardiovascular diseases.
Disclaimer: This information is independently developed by CIMS based on nicardipine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in